Van Hauwermeiren Timothy reported DNLI

Source

Document

SEC Form 4

Publisher

U.S. Securities and Exchange Commission (EDGAR)

Document ID

0001816206-25-000007

Machine-readable

Structured copy

Timestamps

Event (reported)

Nov 4, 2025

Published

Nov 6, 2025

Ingested by INSIDER

Nov 5, 04:34 UTC

Last re-read

Nov 5, 04:34 UTC

Extracted facts

Filer

Van Hauwermeiren Timothy

Role

Director

Transaction

Grant or awardAs filed: “A”

Asset

Denali Therapeutics Inc. — Stock Option (right to buy)

Ticker

DNLI

Shares

31.9K

Price per share

$0

Execution date (reported)

Nov 4, 2025

Owned after transaction

31.9K shares

Days from execution to publication

2

What this establishes

Van Hauwermeiren Timothy filed this Form 4 reporting a grant or award of DNLI on Nov 4, 2025. It became public on Nov 6, 2025. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

Extraction

Method

Form 4 XML

Confidence

1.00

Director

Van Hauwermeiren Timothycik:0001816206

Issuer

Denali Therapeutics Inc.cik:0001714899

Revision history · 0

No field has changed since this record was first ingested.